Create Model Forecasts for Data- Based Decision Making. Patrick J. Park, PharmD, MBA Director, Forecasting & Financial Planning Daiichi Sankyo, Inc.

Similar documents
Forecasting strategies and success factors. March 21, 2017

Infectious Disease. Results 18:1. Campaign Objective. Media Plan. Measuring ROI

Sales/Revenue Forecasting and Contract Analytics that Drive Profitability. March 16, 2015 Presented by: Jag Rajan VP of Finance

Drafting Pharmacy Benefit Manager Contracts: Controlling Costs, Avoiding Hidden Fees

Put Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits

Prescription Medicines: Costs in Context

Sample Job Postings for Entry-Level Pharmacy Technician

Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs

THE BIOLOGIC DRUG MARKET. ebook: The current state of biologic drugs and the challenges ahead

The U.S. Wholesaler Market: Past, Present and Future

Cardinal Health, Inc. (CAH) - Financial and Strategic SWOT Analysis Review

Commercial Pricing and Contracting 101

Global Oncology Biosimilars Market

Strategic Planning Considerations. Presented by: Bruce Maller

White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act

Pharmacy. Medication. Checks

YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.

UTILIZING REAL WORLD BIG DATA AND VISUAL ANALYTICS TO EXAMINE THE PATIENT JOURNEY

Walgreens Rx Supply Chain Transforming to an Outsource Model

Information Systems: Unique Challenges of Managing Medicines Information

Brazil Gastric Balloon Procedures Outlook to 2020

SAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014

France Pressure Relief Devices Market Outlook to 2020

Factors Supporting a Sustainable European Biosimilar Medicines Market PROJECT SUMMARY FOR EXTERNAL COMMUNICATION

EHR AND ERP INTEGRATION. January 25, 2018

Brand Plan Sample Template. Akademia Marketingu Farmaceutycznego

Marketing Analytics II

The Future of Generic Pharmaceuticals

The NBCH PBM Assessment. A Cross-PBM RFI

Specialty Pharmacy: Inside the Innovation. Tim Davis, Pharm.D. General Manager PANTHERx Specialty Pharmacy

MEANINGFUL USE CRITERIA PHYSICIANS

Use of Queuing Models in Health Care - PPT

Henry Ford Health System s Baldrige Journey: Driving Accountability for Excellence. June 25, Kathy Oswald Chief Human Resources Officer

Preparing For & Managing a RADV Audit

Impact of New Proposals on Name Creation for 87 th PTMG Conference Vienna, Austria

A competitive distribution network strategy

Chapter 12. Analytics In Action

Strategy & Planning for Commercial Launch Success in Pharma A Cross-functional Approach

2016 OptumRx Trend Insights

Risk Analysis Overview

Project Management. Objectives 3/17/2015. David Borrill, MT, MBA, PMP

CHARGE DESCRIPTION MASTER (CDM)

WHITE PAPER. Responsive Supply Chain. Abstract

Cindy Kehr Director of Purchasing & Pharmacy Services Keystone Rural Health Center

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

Get Exactly What You Want from Your Next Contract

New Cardinal Health (Post-Spin)

Re-engineering the external drug supply chain

Value Messages: Developing, Incorporating, and Making Use of a Core Strategic Tool

REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013

Best Practices for Program Success. Solutions at the Shelf from Rx EDGE. Rx EDGE. Pharmacy Networks. Media That Delivers

Overview of IMV Data: Perspectives on Large Scale Data Collection. December 8, 2011

National Learning Consortium

Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY

BRIC Surgical Sutures Market Outlook to 2020

The Pharma/Payer Relationship Strategies for the Next Two Years

Global Forum on Competition

5 key steps to boosting Quality of Hire

Looking Ahead The Big Opportunity for Network Design - GST Introduction in India

Introduction of FINESOFT I am FINE with SAP Business One

(Assignment) Master of Business Administration (MBA) PGDPM Subject : Management Subject Code : PGDPM

Shifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go

Question No: 1 ( Marks: 1 ) - Please choose one Marketing plan

Topic 9 Decision making. Higher Business Management

A Hybrid Approach to the Use of Agile in Health IT. Session 147 March 7, 2018 Spencer Reeser-Stout, Senior Project Manager

TABLE OF CONTENTS DOCUMENT HISTORY 5

ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research

Medical Products between

.COM. Pharmaceutical Brand Management Achieving Managed Care Pull-Through Performance

@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015

Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020

Volunteering for Clinical Trials

USP General Chapter <1079> Pharmacopeia Forum. for Drug Products

Supplemental Financial Schedules May 19, 2015

Shaping demands to achieve corporate financial objectives

1/17/2014. Objectives. What is a chart audit? Audits are like mountain biking you must have the right tools to have a successful ride!

STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY

Prescription Writing Version 4.81

Mapping the Patient Journey: Harnessing the power of big data and analytics A FirstWord ExpertViews Dossier Report

NQF registration level. 2 Credit value of qualification 120 ETQA accredited for qualification

Coal cost projections

1.1 Supply Chain Management & Strategic Planning. Supply Chain Evolution The Supercheap Auto Group Story

DEMAND FORECASTING FOR WHOLESALE BUSINESSES

NASDAQ: ATRS. Investor Presentation January 2017

IT Due Diligence in an Era of Mergers and Acquisitions

RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.

3M 360 Encompass System Financial and data quality assurance

Lehman Brothers Global Healthcare Conference

Moving from volume to value in the generic business model

Pharmaceutical Compliance Congress: Pricing Update

September 9, Mr. Mark A. Thierer Chief Executive Officer OptumRx 1600 McConnor Parkway Schaumburg, IL

Jordi Aparici Market Intelligence Consultant

Joshua Ritti. Professional Profile. Academic Credentials & Professional Honors

A critical review of the current landscape Presentations

To provide a framework and tools for planning, doing, checking and acting upon audits

Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device

The Business Development and Financial Reporting Relationship: Forecasting and its Impact on the M&A and Purchase Accounting Process

DLA Troop Support Medical

Transcription:

Create Model Forecasts for Data- Based Decision Making Patrick J. Park, PharmD, MBA Director, Forecasting & Financial Planning Daiichi Sankyo, Inc.

Disclaimer The views and opinions expressed in this presentation are those of the presenters and should not be attributed to Daiichi Sankyo, Inc.

Agenda What is Forecasting? Data Sources for Forecasting Rx Based Forecasting Model Demand Data Ex-Factory Data Inventory Data Patient Based Forecasting Model Market Research Data Probabilistic Forecasting Monte Carlo Simulation Communication

What is Forecasting? to calculate or predict (some future event or condition) usually as a result of study and analysis of available pertinent data - Marriam-Webster s Learner s Dictionary to indicate as likely to occur - Marriam-Webster s Learner s Dictionary Process of gathering information and getting alignment with stakeholders Support decision making process As soon as a forecast is finalized, it is wrong!

Forecasting Method Rx Based Forecasting Often used for in-line products Based on historical data reported by the audits Baseline projection - Trx/Nrx/retail/non-retail Ex-Trend event product life cycle event, promotion impact, market events, market access Patient Based Forecasting Often used for pipeline products with limited history or market Model the entire market for a specific disease state Determine the target population based on product profile

Rx Based Forecasting Using historical data (market/product Trx/Nrx/etc) to create baseline forecasting Audit data (IMS/Symphony) Create Ex-trend events Based on input from marketing/sales/market research Reconciliation/Conversion Inventory data Ex-factory data

Audit Data IMS/Symphony provides Trx/Nrx data based on their pharmacy audit Retail and Mail order pharmacy prescription activity updated weekly/monthly By product/therapeutic class/ payment type/ physician specialty Non-retail data that includes activity from hospital, clinic, and long term care Ex-Factory Data Products shipped from Wholesaler to retail/ nonretail outlets Manufacturer Wholesaler Hospital/ Pharmacy Demand Data captured by IMS/Symphony Patient

Baseline Projection Actual Forecast Market Events Historical trend (both market and product) Historical market events/timing and any inflection point Historical seasonality Future market/product events Additional competitors LOE events

Baseline Projection Many statistical method to use to provide baseline projection Baseline projection can differ based on historical data points inclusion Forecasters insights into the product/market will determine what to include to create the baseline projection Work closely with the stakeholders to pick the most appropriate data points

Ex-Trend Events Consider any market events and product events Competitor entry/ product LOE, etc

Inventory Data and Conversion Bridging Ex-factory and Demand data 852/867 Inventory data Provide data set for manufacturer can use to determine the amount of inventory is in the retail/wholesale channel Baseline Projection Market Events Retail Demand Non Retail Demand Total Demand Gross Sales Ex-Factory Inventory

Patient Based Forecasting Market Research can help provide a lot of data for forecasting input Quan/Qual Market Research Various Database/Reports/ Literature Key Opinion Leaders

Patient Based Forecasting US Population in 2017: (325M) >18yo: 75% (246M) Source: US Census Quick Facts Prevalence: 2.4% (5.9M) Source: Decision Resources / Market Research

Patient Based Forecasting Prevalence: 2.4% (5.9M) Source: MR Diagnosed Moderate: 42.5% (2.5M) Diagnosed Severe: 12.5% (743K) Treated 70% (1.7M) Treated 90% (669K) Treatment 1: 32% Treatment 2: 5% Treatment 1: 39% Treatment 2: 5% Treatment 3: 13%

Patient Based Forecasting Source: US Census Quick Facts Source: Decision Resources/ MR Source: MR Source: Decision Resources/ MR Market Access: 90% Patient Share: 14% Adherence/Compliance: 64% Days of Therapy: 26 days

Forecast Summary

Risk Assessment Assumptions are best guesses Consensus on assumptions are agreed on by stakeholders, but there are other possibilities Leads to many scenarios based on different assumptions what-if analysis Adjust a few assumptions to see what the impact would be Leads to many different variations Communication can be difficult Base case/ Upside/ Downside Pick top few scenarios from what-if

Forecast Assumptions Assumptions Base Case Range Source 1 Launch Date 2017 Assumption 2 Expiry Date 2029 Assumption 3 Prevalence Rate 2.4% Decision Resources 4 Diagnose Rate 55% 50% - 75% Decision Resources 5 Drug Treated Rate 80% 80% - 85% Decision Resources 6 Market Access 90% 7 Moderate Patients Treatment 1 32% MR Treatment 2 5% MR 8 Severe Patients Treatment 1 39% MR Treatment 2 5% 5%-30% MR Treatment 3 13% 10%-40% MR 9 Patient Share % Increase 50% 20% - 50% MR Peak Share 14% Derived - Forecast Pro 10 Market Expansion % 10% 5% - 15% 11 Persistency 83% Decision Resources 12 Compliance 91% Decision Resources 13 Price/Yr $10K 14 Annual Price Increase 5% 3% - 8% 15 GTN 80% Peak Sales $559M

Forecast Assumptions Assumptions Base Case Range Source 1 Launch Date 2017 Assumption 2 Expiry Date 2029 Assumption 3 Prevalence Rate 2.4% Decision Resources 4 Diagnose Rate 55% 50% - 75% Decision Resources 5 Drug Treated Rate 80% 80% - 85% Decision Resources 6 Market Access 90% 7 Moderate Patients Treatment 1 32% MR Treatment 2 5% MR Monte Carlo Simulation can be performed for the range of assumptions 8 Severe Patients Treatment 1 39% MR Treatment 2 5% 5%-30% MR Treatment 3 13% 10%-40% MR 9 Patient Share % Increase 50% 20% - 50% MR Peak Share 14% Derived - Forecast Pro 10 Market Expansion % 10% 5% - 15% 11 Persistency 83% Decision Resources 12 Compliance 91% Decision Resources 13 Price/Yr $10K 14 Annual Price Increase 5% 3% - 8% 15 GTN 80% Peak Sales $559M

Probabilistic Forecast Using value ranges for multiple assumptions and generate output Technique used to understand the impact of risk and uncertainly in assumptions Probabilistic Forecasting helps decision making and any analysis In Monte Carlo simulations, it can run through over 1,000 scenarios and create a range of outputs

Probabilistic Forecast Monte Carlo Simulation on net Sales based on range of inputs on multiple assumptions It will provide probability of net sales range based on the range of assumptions 80% chance that the Net sales will be between $2.5B to $3.9B

Probabilistic Forecast Tornado chart and Sensitivity Analysis Informs us which assumption has the most impact on the forecast Annual price increase has the highest impact on net sales Market expansion has the least impact on net sales

Probabilistic Forecast Creates discussion around the assumptions that has the most impact Be able to identify if any of the assumptions require additional research Adjust range of inputs Eliminate assumptions New assumptions Drives more productive discussion on forecasting assumptions and lead to better decision making Be able to develop more informed forecast

Probabilistic Forecast Opportunity Creates discussion around the assumptions that has the most impact Be able to identify if any of the assumptions require additional research Adjust range of inputs Eliminate assumptions New assumptions Drives more productive discussion on forecasting assumptions and lead to better decision making Be able to develop more informed forecast Challenges Forecast needs to be a number/ target not a range

Forecasting Assumptions 2013 2014 2015 2016 2017 Actual Actual Forecast Forecast Forecast Gross Sales $100M $120M $130M $140M $150M Net Sales $75M $84M $84M $89M $92M Market Growth +5% +7% +8% +8% +8% Market Share 15% 16% 17% 18% 18% TRx Growth +5% +8% +9% +10% +10% Price / Unit $5.12 $5.63 $6.20 $6.81 $7.50 WAC Price Increase Apr 5%; Sep 5% Apr 5%; Sep 5% Apr 5%; Sep 5% Apr 5%; Sep 5% Apr 5%; Sep 5% GTN% 75% 70% 65% 165% 265% A&P $20M $22M $23M $24M $25M Sales Cost $30M $33M $35M $37M $38M

Forecasting Assumptions 2013 2014 2015 Actual Actual Forecast Product A TRx 1.2M 1.26M 1.36M Product Growth (YoY) 2% 5% 8% CVS Health T3 T2 1 of 3 T2 1 of 3 ESI T3 T3 T2 1 of 2 UHC / OptumRx T3 T2 1 of 3 T2 1 of 2 Prime T3 T3 T3 Aetna T3 T2 1 of 3 T2 1 of 2 WAC Price Increase Apr 5%; Sep 5% Apr 5%; Sep 5% Apr 5%; Sep 5% GTN% 75% 70% 65% Gross Sales $100M $120M $130M Net Sales $75M $84M $84M Validate assumptions and get an alignment from the team Build a story to explain changes in assumptions

Net Sales Bridge

Summary As soon as a forecast is finalized, it is wrong! Forecasting is science and art Communicate on changes and assumptions Get an alignment with the stakeholders Be a story teller

Questions?